Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

Hongyu Chen; Junmin Wang; Caiyun Zhang; Peilun Ding; Shuxia Tian; Junming Chen; Guang Ji; Tao Wu

doi:10.1016/j.biopha.2022.113341

Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

Biomed Pharmacother. 2022 Sep:153:113341. doi: 10.1016/j.biopha.2022.113341. Epub 2022 Jul 1.

Authors

Hongyu Chen¹, Junmin Wang², Caiyun Zhang², Peilun Ding², Shuxia Tian³, Junming Chen⁴, Guang Ji⁵, Tao Wu⁶

Affiliations

¹ Minhang Hospital, Fudan University, Shanghai 201199, China; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
² Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
³ Minhang Hospital, Fudan University, Shanghai 201199, China.
⁴ Minhang Hospital, Fudan University, Shanghai 201199, China. Electronic address: chjm2008@126.com.
⁵ Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. Electronic address: jg@shutcm.edu.cn.
⁶ Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: wutao001827@163.com.

PMID: 35785704
DOI: 10.1016/j.biopha.2022.113341

Abstract

Sphingosine 1-phosphate receptor (S1PR), as a kind of G protein-coupled receptor, has five subtypes, including S1PR1, S1PR2, S1PR3, S1PR4, and S1PR5. Sphingosine 1-phosphate receptor (S1P) and S1PR regulate the trafficking of neutrophils and some cells, which has great effects on immune systems, lung tissue, and liver tissue. Presently, many related reports have proved that S1PR has a strong effect on the migration of lymphocytes, tumor cells, neutrophils, and many other cells via the regulation of signals, pathways, and enzymes. In this way, S1PR can regulate the relative response of the organism. Thus, S1PR has become a possible target for the treatment of autoimmune diseases, pulmonary disease, liver disease, and cancer. In this review, we mainly focus on the research of the S1PR for the new therapeutic directions of different diseases and is expected to assist support in the clinic and drug use.

Keywords: Cancer; Immune system; Liver disease; Pulmonary disease; S1P; S1PR.

Publication types

Review

MeSH terms

Humans
Neoplasms* / drug therapy
Receptors, Lysosphingolipid* / metabolism
Sphingosine-1-Phosphate Receptors

Substances

Receptors, Lysosphingolipid
Sphingosine-1-Phosphate Receptors